Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

Raw, unpasteurized milk has gained traction in the US over the past two years despite warnings about its health risks. The American Academy of Pediatrics (AAP) has renewed its call for a ban on the sale and distribution of raw milk and dairy products, including raw cheeses.

Recent cases have highlighted the risks associated with raw milk. Two California girls — 17-month-old Brooklyn and 6-year-old Victoria — were hospitalized with near-fatal E. coli infections after drinking raw goat milk. Hundreds of people have fallen ill across nine states in the past two years after consuming raw milk or products made from it.

“Claims that raw milk provides superior health benefits are not supported by scientific evidence,” the AAP said.

Raw Milk Riskier For Children, Pregnant People

Also read: Drinking Raw Milk Hospitalizes 2 Young Girls in US With Nearly Fatal E. Coli Infection: Health Risks Explained

In a policy statement published online ahead of print in the November 2026 issue of Pediatrics, the AAP said unpasteurized milk, cheese and other raw dairy products are unsafe, particularly for young children and people who are pregnant or breastfeeding.

“Nearly half of illnesses caused by raw dairy consumption occur in people under age 20 – and a significant share of those cases are in children under 5,” said Adam J. Ratner, MD, MPH, FAAP, lead author.

“These illnesses can be severe and lead to life-threatening complications. Pasteurization … dramatically reduces the risks without taking away the nutritional value families rely on.”

H5N1 Adds To Raw Milk Concerns

The updated guidance also highlights H5N1, or highly pathogenic avian influenza, as an emerging risk associated with raw milk. Sales and distribution of raw milk remain legal in at least 27 states.

The virus can be transmitted from infected dairy cattle into milk, where it can reach high concentrations and remain detectable in refrigerated raw milk for up to five weeks.

During the 2024 US dairy outbreak, infectious H5N1 was detected in nearly one-quarter of raw milk samples in affected areas. However, FDA and USDA testing of commercial pasteurized milk found no viable virus, showing that high-temperature, short-time (HTST) pasteurization neutralizes H5N1.

No human cases of H5N1 infection from consuming raw milk have been confirmed to date, but the AAP considers it a credible emerging threat.

Read More: Second Plague Death Reported As Russia Denies Outbreak

Raw Milk Can Carry Dangerous Pathogens

Unpasteurized milk can contain Listeria, E. coli, Salmonella, Campylobacter and Brucella. These infections can cause severe illness, hospitalization, miscarriage and death, particularly among young children, pregnant people and those with weakened immune systems.

Listeriosis is estimated to be 12 to 14 times more common during pregnancy than in the general population and can cause miscarriage, stillbirth, premature delivery or severe illness in newborns.

AAP Says Pasteurized Dairy Is Safest

“Parents may choose raw milk because they have heard it is healthier or more natural, but the scientific evidence tells a different story,” said Mark R. Corkins, MD, FAAP, co-author of the policy statement.

“Pasteurized dairy products provide the same essential nutrients without exposing children and families to preventable infections from dangerous bacteria and viruses. For infants, children and pregnant people, pasteurized dairy products are clearly the safest choice.”

Women living with HIV are six times more likely to be infected with HPV. They are also twice as likely to die from invasive cervical cancer. Hence, a recent study published in The Lancet HIV has sparked hope after it found that HPV vaccine can provide long-term safety to women living with HIV.

Emphasising on the importance of HPV vaccination among women in this sub-section, the study followed women with HIV for 9 years after they received HPV vaccine, becoming the longest study that analyses how this vaccine works in this population. Until now, researchers had limited evidence about how this vaccine's efficacy on women with HIV.

About The HPV Vaccination Study On Women With HIV

Also read: India-Made HPV Vaccine CERVAVAC Gets WHO Prequalification: Serum Institute

A team of researchers from the UBC Faculty of Medicine followed 293 Canadian women with HIV through 14 HIV and gynecological treatment clinics across the country. They found that the vaccine evoked a strong immune response that persisted for a long time.

The rates of HPV infection and genital warts were very low among women who received all the three doses did not already have the strains of HPV targeted by the vaccine.

Additionally, no participants developed serious precancerous changes to the cervix caused by those HPV strains.

Maintaining an undetectable HIV viral load was also crucial for sustaining HPV antibody levels over time, according to the researchers. The finding highlighted the importance of continued access to appropriate HIV treatment and care.

“We’ve known for some time that HPV vaccines are safe and highly effective, but we didn’t have long-term evidence to show how lasting that protection is for women living with HIV,” said first author Dr. Elisabeth McClymont, assistant professor in the UBC Faculty of Medicine’s department of obstetrics and gynaecology and department of pediatrics. “Our findings are incredibly reassuring. Even in a population whose immune systems can be affected by HIV, vaccination provided strong protection against HPV infection and cervical cancer for many years.”

Worldwide HIV Burden In Women

Also read: H. pylori, HPV Among Five Infections Behind 1 In 8 Cancers Worldwide: Lancet

The findings have significant relevance globally as almost 20 million women and girls are living with HIV worldwide. It is also uneven as regions like sub-Saharan Africa face a heavier burden with limited access to cervical cancer screening and treatment.

“Cervical cancer is preventable, yet it continues to take lives in Canada and around the world, particularly in places where HIV rates are higher and access to screening and prevention is limited,” said senior author Dr. Deborah Money, professor and head of the UBC Faculty of Medicine’s department of obstetrics and gynaecology. “We now have concrete evidence that HPV vaccination works very well for women living with HIV over the long term. Making this vaccine more accessible and acceptable for those who need it most can help us prevent unnecessary deaths and move closer to eliminating cervical cancer globally.”

HPV & Cervical Cancer

Most cervical cancer cases are caused by infection from oncogenic types of human papillomavirus (HPV). HPV is a common sexually transmitted infection which can affect the throat, skin, genitals, and anal region.

Persistent HPV infection may lead to precancerous changes in the cervix, which if left untreated, is most likely to result in cervical cancer within a span of two decades. Women with HIV, with weakened immune systems, may develop cervical cancer within 5 to 10 years.

According to the World Health Organisation, cervical cancer is the fifth most diagnosed cancer forms among women. In 2024, more than 600,000 cases and 280,000 deaths were reported. The health body emphasises on prevention through HPV vaccination and regular screening.

Even as Bangladesh grapples with a significant measles burden, the country is now facing one of its worst dengue outbreaks.

According to health ministry data, more than 90,350 people have been hospitalised and 281 deaths reported since the beginning of the year.

In October alone, 10,736 people have been hospitalized and 36 have died, raising concerns that the outbreak could worsen.

Dengue Death Toll Among Highest Recorded

The death toll of 281 makes this the fourth-highest annual figure since Bangladesh’s first major dengue outbreak in 2000.

According to the Directorate General of Health Services, the highest number of dengue deaths was recorded in 2023, when 1,705 people died.

A death review by the Institute of Epidemiology Disease Control and Research (IEDCR), led by its Director Prof Quazi Ahmed Zaki, found that more than one-third of dengue patients who died did so within a day of hospital admission.

The review of 119 deaths also found that many patients had experienced delays of at least three days before being diagnosed, according to Prof Zaki, as reported by The Daily Star.

All 4 Dengue Serotypes Active

Also read: Dengue Is Spreading Beyond Monsoons And Into New Regions Across India, Says Expert

Medicine specialist Dr ABM Abdullah said repeated infections and delayed diagnosis were contributing to severe cases and deaths.

People previously infected with dengue could face a higher risk of severe illness during subsequent infections, he said.

“Dengue has four serotypes. When people are infected for the first time, they often do not realise that they have dengue. They may mistake the symptoms for influenza or another common illness and recover without serious complications,” he said.

However, subsequent infections can be more severe, particularly when a person contracts dengue for the second, third or fourth time, he added.

Prof Abdullah said dengue had also become harder to recognize early, with some patients developing mild or non-specific symptoms such as low-grade fever, body aches, a runny nose or cough.

“The problem is that patients often do not realize that they have dengue. By the time they are diagnosed, their condition may have become serious, leaving doctors with limited options,” he said.

He urged people to undergo dengue testing if they develop fever, body aches, headache, cold or other mild symptoms while dengue is circulating.

Bangladesh Considers Dengue Vaccine Trials

Read More: QDENGA: India’s First Approved Dengue Vaccine May Hit Shelves In 2027; How Effective Is It?

Amid the rising cases and deaths, Bangladesh is considering clinical trials of a dengue vaccine, Reuters reported.

Recent rainfall has created favorable conditions for mosquito breeding, raising concerns that the outbreak could worsen.

State Minister for Health M.A. Muhit said as all four dengue serotypes had been detected in Bangladesh, increasing the possibility of repeated infections because immunity to one serotype does not protect against the other three.

"With all four dengue serotypes now circulating in Bangladesh, we are considering conducting vaccine trials in the country," Muhit said.

Health experts have said dengue is no longer concentrated only in major cities and that spraying alone will not curb transmission unless mosquito breeding sites are eliminated.

The government is considering a dengue vaccine as a long-term measure to reduce infections and deaths, but there are no immediate plans to begin vaccination.

“We are discussing vaccines as a long-term measure. There are probably three dengue vaccine candidates in the world at present. We are also considering the issue in Bangladesh, but it is not happening at this moment,” Muhit said.